Drugs / KH658
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06825858 | Apr 2025 → Jan 2027 expected | age-related macular degeneration | Chengdu Origen Biotechnology Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06458595 | Jun 2024 → Mar 2026 overdue | age-related macular degeneration | Chengdu Origen Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KH658 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06825858 ↗ |
| Action | Inhibit | “inhibits VEGF” NCT06825858 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “adeno-associated virus (AAV) vector-based gene therapy” NCT06458595 ↗ |
| Route | Other | “for suprachoroidal space injection” NCT06458595 ↗ |